GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 1, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

GR1803 injection

D1 given at a dose of 30ug/kg, D4 given at a dose of 90ug/kg, D8 given at a dose of 180ug/kg, followed by weekly dosing up to cycle 9, and cycle 10 and onwards, every 2 weeks, with a dosing cycle of every 4 weeks

Trial Locations (1)

310003

RECRUITING

he First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY